{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 52,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The table segments patients into kinase inhibitor naïve and those with 1 prior inhibitor, further sub-segmented by mutation type (G2032R vs Non-G2032R).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/10",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.015,
        "w": 0.435,
        "x": 0.076,
        "y": 0.901
      },
      "kind": "source-note",
      "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e36a399-771c-49cf-bc37-18f8463fb3de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.515,
        "w": 0.864,
        "x": 0.068,
        "y": 0.285
      },
      "kind": "table",
      "text": "Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83686516-3c1d-4a1c-b2b8-d0e6641e1a28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.695,
        "x": 0.076,
        "y": 0.188
      },
      "kind": "title",
      "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6031f80-21ba-44e4-abc8-5cf6a955adfb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.415,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "ROS1-positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db3454c1-26b0-402f-8044-8665d6f699c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "04b8175b-2096-438a-b3d9-88440fa24f94",
      "evidence": "table/data: Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "1bb8c0b5-57e2-4bb0-9d13-ed06ee6a7e1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Slide 10: ROS1-positive NSCLC Market Overview",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "65aac5b7-e703-47fe-855e-79b350b26916",
      "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions",
      "position": 0,
      "objective": "What is the cost of not addressing drug resistance in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}